Sentences with phrase «cell and gene therapy clinical»

Clinical Pharmacology Research Track Neuro - oncology Clinical Research Track Cell and Gene Therapy Clinical Research Track Leukemia Clinical Research Track Solid Tumor Clinical Research Track

Not exact matches

US - based pharmaceutical company Gilead Sciences entered the chimeric antigen receptor (CAR) T - cell therapy business through its acquisition of Kite Pharma, and Australian biopharma company CSL Behring acquired US - based Calimmune, a company that develops clinical - stage gene therapy solutions.

With major clinical successes in areas such as CAR - T, gene therapy, immune - oncology, cell therapy and gene editing, many see 2017 as the year that biotech really came of age.

Priscilla N. Kelly Associate Editor Education: B.Sc., University of Western Australia; Ph.D., University of Melbourne Areas of responsibility: Preclinical development, translational medicine, cancer immunotherapy, drug discovery, clinical trials, gene and cell therapy E-Mail: [email protected]

Muscle biologists Qi Long Lu and Terence Partridge at the Medical Research Council Clinical Sciences Centre in London, U.K., and their colleagues decided to combined the antisense strategy with a chemical often used in gene therapy because it is known to improve delivery of DNA into cells.

It showed effectiveness against liver cancer in a phase II clinical trial and will move into a phase III trial later this year, David Kirn, an oncologist and the company's president and chief executive officer, said at a recent meeting of the American Society for Gene & Cell Therapy in Washington, D.C..

The proposed clinical trial, in which researchers would use CRISPR to engineer immune cells to fight cancer, won approval from the Recombinant DNA Advisory Committee (RAC) at the U.S. National Institutes of Health, a panel that has traditionally vetted the safety and ethics of gene therapy trials funded by the U.S. government and others.

Dr. Levine directs the Clinical Cell and Vaccine Production Facility (CVPF), which develops, manufactures, and tests novel cell and gene therapies in clinical trials at Penn and collaborating instiClinical Cell and Vaccine Production Facility (CVPF), which develops, manufactures, and tests novel cell and gene therapies in clinical trials at Penn and collaborating institutiCell and Vaccine Production Facility (CVPF), which develops, manufactures, and tests novel cell and gene therapies in clinical trials at Penn and collaborating instituticell and gene therapies in clinical trials at Penn and collaborating insticlinical trials at Penn and collaborating institutions.

Boston Children's Hospital has offered non-exclusive licenses to for - profit entities on a patent developed by Orkin's laboratory regarding BCL11A, a genetic switch regulating hemoglobin production that is expected to form the basis of clinical trials for gene therapy and gene editing for sickle cell disease and thalassemia.

In this way we hope to lay a clinical groundwork for two new techniques: liver cell transplantation and liver gene therapy.»

It is the first time that a gene therapy based on genetically modified stem cells is tested in a multicenter, international clinical trial that shows a reproducible and robust therapeutic effect in different centers and different countries.

«RNAi therapies are a unique approach to cancer treatment as they have the potential to «turn off» the genes» coding for proteins involved in cancer cell division,» said Ramesh K. Ramanathan, M.D., medical director of the Virginia G. Piper Cancer Center Clinical Trials Program at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz. «Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth.»

Colleen Dansereau, RN, MSN, CPN Program Manager, Gene Therapy Program As manager of the Gene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease (CGene Therapy Program As manager of the Gene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous diseaseTherapy Program As manager of the Gene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease (CGene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous diseaseTherapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous diseasetherapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease (Cgene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous diseasetherapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease (CGD).

World Stem Cell Summit and Phacilitate are proud to present a the 3 - day EMERGING SCIENCE track covering ONCOLOGY, TRANSLATIONAL & CLINICAL UPDATE and GENE THERAPY FOR RARE DISEASES.

Chris is on a number of national and international committees, working groups and initiatives related to the academic, clinical translation and commercialization of cell and gene therapies including; Founder and CEO of the London Regenerative Medicine Network (LRMN), Founding Member of the UK - Israel Science Council, Scientific Advisory Board of the UK Cell and Gene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell Netwcell and gene therapies including; Founder and CEO of the London Regenerative Medicine Network (LRMN), Founding Member of the UK - Israel Science Council, Scientific Advisory Board of the UK Cell and Gene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell Netwgene therapies including; Founder and CEO of the London Regenerative Medicine Network (LRMN), Founding Member of the UK - Israel Science Council, Scientific Advisory Board of the UK Cell and Gene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell NetwCell and Gene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell NetwGene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell NetwCell Network.

Prior to that, Dr. Matushansky was at Novartis where he was Global Head for Clinical and Scientific Development at its Gene & Cell Therapy Unit as well as a Global Clinical Program Lead within Novartis» Oncology Translational Medicine Unit.

He is Professor of Cell and Gene Therapy in the Advanced Centre for Biochemical Engineering, University College London working on the clinical translation and commercialization of cell and gene therapCell and Gene Therapy in the Advanced Centre for Biochemical Engineering, University College London working on the clinical translation and commercialization of cell and gene therapGene Therapy in the Advanced Centre for Biochemical Engineering, University College London working on the clinical translation and commercialization of cell and gene therapcell and gene therapgene therapies.

Dr. Sadelain is a member of the American Society of Hematology, the American Society of Human Genetics, and the American Society of Cell and Gene Therapy, where he served on the board of directors from 2004 to 2007, and is an elected member of the American Society for Clinical Investigation.

Gene and cell therapies have made important medical advances over the past three decade, developing technologies and testing novel therapies in multiple human clinical trials of many diseases.

The program is unique in its concentration of nationally and internationally recognized leaders in the areas of new drug development, cell and gene therapy and design and conduct of both local and national clinical trials through the Children's Oncology Group (COG).

«Having a very efficient and practical way of generating patient - specific stem cells, which unlike human embryonic stem cells, wouldn't be rejected by the patient's immune system after transplantation brings us a step closer to the clinical application of stem cell therapy,» says Belmonte, PhD., a professor in the Gene Expression Laboratory and director of the Center of Regenerative Medicine in Barcelona, Spain.

Tags: Clinical Research, defeatHIV, the Delaney Cell and Genome Engineering Initiative, gene therapy, Hans - Peter Kiem, hiv, HIV cure, Keith Jerome, retrovirus, Vaccine and Infectious Disease

Overall, SR - Tiget represents a multi-disciplinary research environment, which provides a unique blend of scientific expertise in the development of innovative gene and cell therapy strategies, access to relevant preclinical models to evaluate their efficacy and safety, as well as competence in conducting early phase clinical trials.

This is a structured program in which trainees receive in - depth education through a core clinical research curriculum and participation in clinical research training in one of five specialized training tracks: clinical pharmacology, neuro - oncology, cell and gene therapy, leukemia or solid tumor.

«The Department of Health and its Gene Therapy Advisory Committee are currently working with other regulators in the field to produce a «Regulatory Route Map» to provide further clarity on the regulatory requirements for the clinical use of stem cells.»

Clinical and Regenerative medicine refers to development and implementation of advanced therapeutic approaches that may involve the support of expertise in gene / cell therapy, tissue engineering, pharmacology and pharmacogenomics, development of novel molecular target therapy.